Automating the design of antimicrobial peptides, which can be used to combat antimicrobial-resistant bacterial strains, was the key motivation for developing Argonne’s BIO-Workcell. This proof of concept was demonstrated on E. coli bacterial strains using high-throughput screening techniques in concert with state-of-the-art artificial intelligence. This approach shows promise for accelerating the drug discovery process, making it faster and more efficient to identify potential therapeutic compounds.